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Abstract 
Aims. Dysregulation of the bone morphogenetic protein receptor type 2 (BMPR2) is a hallmark 
feature that has been described in several forms of pulmonary hypertension. We recently identified the 
microRNA miR-20a within a highly conserved pathway as regulator of the expression of BMPR2. To 
address the pathophysiological relevance of this pathway in vivo, we employed antagomiR-20a and 
investigated whether specific inhibition of miR20a could restore functional levels of BMPR2 and, in 
turn, might prevent pulmonary arterial vascular remodelling. 
Methods and results. For specific inhibition of miR-20a, cholesterol modified RNA oligonucleotides 
(antagomiR-20a) were synthesized. The experiments in mice were performed by using the hypoxia-
induced mouse model for pulmonary hypertension and animal tissues were analysed for right 
ventricular hypertrophy and pulmonary arterial vascular remodelling. Treatment with antagomiR-20a 
enhanced the expression levels of BMPR2 in lung tissues; moreover, antagomiR-20a significantly 
reduced wall thickness and luminal occlusion of small pulmonary arteries and reduced right 
ventricular hypertrophy. To assess BMPR2 signalling and proliferation, we performed in vitro 
experiments with human pulmonary arterial smooth muscle cells (HPASMC). Transfection of 
HPASMC with antagomiR-20a resulted in activation of downstream targets of BMPR2 showing 
increased activation of Id-1 and -Id2. Proliferation of HPASMC was found to be reduced upon 
transfection with antagomiR-20a. 
Conclusion. This is the first report showing that miR-20a can be specifically targeted in an in vivo 
model for pulmonary hypertension. Our data emphasize that treatment with antagomiR-20a restores 
functional levels of BMPR2 in pulmonary arteries and prevents the development of vascular 
remodelling.  
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Introduction 
Vascular remodelling of small pulmonary arteries is, together with vasoconstriction and 
microthrombosis, one of the pathogenetic hallmarks of pulmonary arterial hypertension (PAH). 
However, it is largely unknown what causes vascular remodelling or how it can be treated. Genetic 
mutations of the bone morphogenetic protein receptor type II (BMPR2), a member of the transforming 
growth factor (TGF-) β family expressed on the surface of endothelial and vascular smooth muscle 
cells of the pulmonary arterial circulation, have been described in familial and idiopathic PAH 1, 2. 
Moreover, reduced expression of BMPR2 without concomitant mutations has also been found in other 
forms of pulmonary hypertension including established animal models of the disease  3, 4, 5. It has been 
debated controversially whether the altered expression of BMPR2 due to mutations or downregulation 
might have a functional readout and, thus, an impact on the pathogenesis of PAH. Two recent studies 
however have underscored the potential role of BMPR2-mediated signalling for vascular remodelling 
6, 7. Long and coworkers observed that dysfunctional BMPR2/TGF-β signal transduction results in 
altered expression of transcription factors including Smads and Id (inhibitor of DNA binding) leading 
to migration of vascular smooth muscle cells 6. Similar findings have been reported by another study 
showing that heterogeneous mutations of BMPR2 are associated with disrupted Smad signalling 
resulting in a pro-proliferative and anti-apoptotic phenotype of pulmonary arterial smooth muscle cells 
7. 
MicroRNAs (miRNAs) comprise a class of small, non-coding RNA molecules that regulate gene 
expression on the post-transcriptional level 8; miRNAs preferentially bind to conserved regions in the 
3’ untranslated region (UTR) of their target genes and either suppress the translation or the mRNA 
stability of these genes 9. There is a growing body of evidence that the abnormal expression of 
miRNAs modulates human diseases by regulating key molecules of apoptosis, proliferation or cell 
signalling 10. Conversely, efficient and non-toxic inhibition of miRNAs in vivo is of particular interest 
since such methods would offer a therapeutic approach to suppress altered miRNA expression in 
human disease. Krutzfeldt and co-workers recently described the inhibition of miRNAs by the 
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application of small anti-sense RNA molecules conjugated with cholesterol called antagomiRs in mice 
11.  
We have recently proposed that miRNAs might regulate the expression of BMPR2 and identified a 
phylogenetically conserved pathway involving the action of the signal transducer and activator of 
transcription (STAT)3 and the microRNA cluster miR-17/92, mainly of miR-20a 12. Others have 
emphasised this hypothesis by showing that miRNAs derived from miR- 17/92 are over expressed in 
experimental pulmonary hypertension in vivo 13 making these miRNAs interesting targets for further 
investigations. With respect to pathogenesis and therapy, this model offers the potential to restore 
functional expression levels of BMPR2 by antagonising distinct miRNAs.  
In the present study, we addressed feasibility and functional readout of specific antagonisation of 
miR20-a by using antagomiR in an animal model of hypoxia-induced pulmonary hypertension in vivo 
and in vitro. 
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Methods 
Animal experiments 
Male mice (BL6) were obtained by the Institute for Veterinary Physiology at the University of Zurich. 
A total of 40 animals was used, 8 of these were employed to adjust dosage and timing of the 
intraperitoneal (i.p.) applications of antagomiR-20a (pre-test). The study design of the in vivo 
experiments is provided in Figure 1a. Four groups were used (n= 8 each): 3 groups were employed in 
hypoxic conditions. The fraction of oxygen was decreased gradually from 21% to 10% over 60 
minutes. Hypoxic conditions were provided by chambers connected to a gas mixer (Ruskinn Life 
Science). Animals were treated with antagomiR-20a (25 mg/kg), antagomiR negative control 
(antagomiR_MM) or PBS, respectively. Injections were performed at baseline (day 0) with boosters 
performed at day 5 and 12. One group of animals was used as normoxic controls. Mice were assessed 
daily for activity and well-being. Food and water was provided ad libitum. Blood analysis, 
morphometry and tissue preparation for later analysis were performed on day 21. The experiments 
were approved by Zurich Canton’s Veterinary office. To assess morphometry, hearts and lungs were 
removed, formalin-fixed without prior perfusion, paraffin-embedded and stained with hematoxylin and 
eosin. Parameters including heart hypertrophy, cell wall thickness, and vessel occlusion were 
determined by using the MCID analysis program 7.0 (InterFocus Imaging, Cambridge, UK).  
AntagomiR design 
Cholesterol modified RNA oligonucleotides (antagomiRs) directed against human and murine  
miR-20a (MIMAT0000529) were designed as described (11) and synthesized by Microsynth 
(Microsynth, Balgach, Switzerland). As a negative control, twelve point mutations were introduced 
into the miR-20a mature sequence (antagomiR_MM) creating a RNA sequence which is not encoded 
in the murine or human genome. The sequences are the following: antagomiR-20a (5’ – CUA CCU 
GCA CUA UAA GCA CUU UA – 3’), antagomiR_MM (5’ – GAC CGU UCA CUA UUA CGA 
GUC AA – 3’). 
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Statistics 
For statistical analysis, GraphPad Prism Software (GraphPad Software, San Diego, CA, USA) was 
used. To compare samples with parametric distribution, the paired or unpaired t-test was applied and a 
p-value < 0.05 was considered to be statistically significant (* p < 0.05, ** p < 0.01, *** p < 0.001). For 
statistical analysis between more than two groups one-way ANOVA (Tukey post-test) was used. In all 
statistical analyses, two sided tests were applied. A table showing all statistical analyses is provided 
(Suppl. table 1). All data are shown as mean ± SD. 
Extensive materials and methods are provided in the online supplement. 
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Results 
Application of antagomiR-20a suppresses miR-20a expression in target tissues 
We recently identified a novel signalling pathway that regulates the expression of BMPR2 through the 
action of miR-20a 12. Here we addressed the implications of this pathway in an animal model of 
hypoxia-induced pulmonary hypertension.  The in vivo experiments were performed as described in 
the Methods (Fig. 1a). As shown in Figure 1b, repeated intraperitoneal injections of antagomiR-20a 
significantly down regulated the expression levels of miR-20a in lung tissues when assessed by qPCR 
at day 21. AntagomiR-20a treated animals showed an expression level of miR-20a of ∆Ct 3.68 ± 0.58 
as compared to ∆Ct 2.31 ± 0.23 in normoxic control animals thus resulting in a reduction of 59.3% (p 
< 0.001). On the other hand, no significant changes were observed between normoxic control mice and 
antagomiR_mismatch (antagomiR_MM, ∆Ct 2.46 ± 0.2) or PBS (∆Ct 2.18 ± 0.26) treated animals. 
Similar results were observed for other tissues analysed, in particular heart and liver (data not shown). 
These data indicate that intraperitoneally injected antagomiRs are not subjected to a significant hepatic 
first-pass effect and, thus, are a feasible approach to inhibit the expression of distinct miRNAs in 
target tissues including the lungs. The sequences of antagomiR-20a and antagomiR_MM are provided 
in Figure 1c. 
AntagomiR-20a prevents the development of hypoxia-induced morphological changes within the 
cardiopulmonary circulation 
Morphometric analyses were performed to assess the functional and hemodynamic consequences of 
reduced expression levels of miR-20a achieved by the application of antagomiR-20a. Representative 
images of pulmonary arterioles stained for α-smooth muscle actin are shown in Figure 2a; treatment 
with antagomiR-20a significantly inhibited the vascular remodelling observed in PBS and 
antagomiR_MM treated hypoxic animals. Computer-based analysis further quantified the occlusion of 
these vessels to be reduced from 13.47 ± 0.73 and 13.33 ± 0.61 (antagomiR_MM and PBS treated 
animals, respectively) to 7.72 ± 0.93 in antagomiR-20a treated mice or to 1.73 ± 0.48 in normoxic 
controls (Fig. 2b). Similar effects were observed for the thickness of the vessel wall showing a 
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reduction from 1.18 ± 0.06 µM and 1.28 ± 0.15 µM in antagomiR_MM and PBS treated animals to 
0.96 ± 0.05 µM in antagomiR-20a treated animals (0.71 ± 0.04 µM in normoxic controls; Fig. 2c).  
Right ventricular hypertrophy, assessed in Figure 2d, after 10% O2 for 21 days was strongly reduced in 
animals receiving antagomiR-20a when compared to hypoxic mice treated with antagomiR_MM or 
PBS (representative images are shown in Fig. 2d). These results were confirmed by calculating heart 
weight relative to body weight (antagomiR_MM: 0.0061 ± 0.0006 vs. antagomiR-20a: 0.0056 ± 
0.0007; Fig. 2e) and by the relation of the right ventricular to the left ventricular volume (RV/LV + S; 
antagomiR_MM: 0.25 ± 0.01; antagomiR-20a: 0.21 ± 0.01; Fig. 2f), indicating that the right 
ventricular afterload was reduced in antagomiR-20a treated mice as compared to mock-treated 
hypoxic animals. Blood analysis performed at day 21 revealed that hypoxia resulted in erythrocytosis, 
which was most prominent in hypoxic PBS-treated animals (Fig. 2g). Whereas significant differences 
were observed between normoxic controls (11.63 ± 0.91 g/dl) and all hypoxic groups (20.23 ± 2.04 
g/dl for antagomiR-20a, 21.75 ± 1.28 g/dl for antagomiR_MM, and 23.27 ± 1.31 g/dl for PBS, 
respectively), differences between antagomiR-20a and antagomiR_MM treated animals did not reach 
statistical significance. 
These data imply that the pathomorphological sequelae of hypoxia on the pulmonary vasculature, 
which lead to the development of pulmonary hypertension and, subsequently, to right ventricular 
hypertrophy, can be prevented by the application of antagomiR-20a.  
AntagomiR-20a restores functional expression levels of BMPR2 in mice 
Since we hypothesized that the reduced expression levels of BMPR2 observed in pulmonary 
hypertension might be due to targeted inhibition by miR-20a 12, we next investigated whether the 
application of specific antagomiRs to mice increase BMPR2 expression levels, and whether 
restoration of this receptor might have functional implications. As shown in Figure 3a, the mRNA 
expression levels of BMPR2 in lung tissue were found to be reduced in both hypoxic control groups 
(antagomiR_MM: ∆Ct 3.36 ± 0.73; PBS: ∆Ct 3.2 ± 0.41) when compared to normoxic mice (∆Ct 2.61 
± 0.19). Interestingly, mRNA levels of BMPR2 under hypoxic conditions could be normalised to the 
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levels observed in normoxic control animals by the application of antagomiR-20a (∆Ct 2.68 ± 0.16, 
Fig. 3a). These findings are further illustrated by immunohistochemical and Western blot analysis 
using antibodies directed against BMPR2 showing that the application of antagomiR-20a increased the 
expression of BMPR2 on endothelial and smooth muscle cells of pulmonary arterioles as compared to 
antagomiR_MM injected mice (Fig. 3b) and PBS treated hypoxic mice (Fig. 3c, Western blots 
provided as supplementary Fig. S1).   
Similarly, Smad5 and Id-2, two validated signalling elements downstream of the BMPR2 pathway 14 
showed enhanced expression levels in lung tissues of animals treated with antagomiR-20a as 
compared to hypoxic controls (Smad5: antagomiR-20a ∆Ct 3.89 ± 0.2 vs. hypoxia PBS ∆Ct 4.16 ± 
0.26, Fig. 3d; Id-2: antagomiR-20a ∆Ct 5.09 ± 0.46 vs. hypoxia PBS ∆Ct 5.68 ± 0.52, Fig 3e). 
Expression levels for Id-1, however, were not found to be changed in normoxic or hypoxic animals 
(Supplementary Fig. S2). Protein analysis by Western blotting for Id-2 further confirmed these 
findings and are provided as supplementary information (Supplementary Fig. S3). These data suggest 
that treatment with antagomiR-20a increases expression levels of BMPR2 within the pulmonary 
vasculature and, most important, restored functional BMPR2 signalling.  
AntagomiR-20a enhances BMP-2 mediated signalling in vitro 
Upon binding of the ligand BMP-2 to BMPR2, Smad5 is activated by phosphorylation, which, in turn, 
activates the transcription factors Id-1 and -2. Since treatment with antagomiR-20a up regulated the 
expression levels of BMPR2 in vivo, we next investigated whether antagonisation of miR-20a might 
also enhance the BMP-2 mediated signalling in vitro. We thus utilised human pulmonary arterial 
smooth muscle cells (HPASMC) that were stimulated with BMP-2 for different time periods and 
found that treatment with antagomiR-20a enhanced BMPR2-induced signalling activity, i.e. the 
expression levels of Id-1 and -2 showed an augmentation of the BMP-2 mediated induction of gene 
expression by transfection of antagomiR-20a. As shown in Fig. 4a, 1h of BMP-2 stimulation enhanced 
the mRNA levels of Id-1 in antagomiR-20a treated cells by 2.65 ± 1.55 fold (as compared to 1.52 ± 
0.5 fold in antagomiR_MM transfected cells, p = 0.102). After 4h of BMP-2 stimulation Id-1 was 
significantly more induced in HPASMC treated with antagomiR-20a (4 ± 2.28) as compared to control 
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cells (3 ± 2.14, p = 0.035). The mRNA levels of Id-2, on the other hand, were found to be significantly 
more elevated by BMP-2 stimulation in antagomiR-20a treated HPASMC after 1h only 
(antagomiR_MM: 1.14 ± 0.31 fold, antagomiR-20a: 1.65 ± 0.41 fold, p = 0.02, Fig. 4b). 
Finally, promoter studies were performed to illustrate an enhancement of BMP-2 signalling by 
antagonising miR-20a. The promoter of Id-1 containing multiple Smad transcription factor binding 
sites 15 was cloned into a luciferase-based reporter gene vector. As shown in Fig. 4d, 4h of BMP-2 
stimulation induced the relative promoter activity of Id-1 by 1.38 ± 0.22 fold in antagomiR_MM 
transfected cells. Interestingly, the increase in promoter activity upon stimulation with BMP-2 was 
significantly more enhanced when cells were transfected with antagomiR-20a (1.69 ± 0.22 fold, 
p=0.016). Conversely, the over expression of miR-20a by transfection of small RNA oligonucleotides 
(mat-miR-20a) reduced the BMP-2 mediated induction of the promoter activity of Id-1 (mat-
miR_MM: 1.81 ± 0.27 fold; mat-miR-20a: 1.47 ± 0.35 fold, p = 0.013; Fig. 4e).  
Note that, Smad5 was predicted to be directly targeted by miR-20a (TargetScan, Whitehead Institute 
for Biomedical Research, www.targetscan.org, 16). Accordingly, the expression of Smad5 after 
silencing of miR-20a in HPASMC was analysed. As shown in supplementary Fig. S4, transfection of 
antagomiR-20a significantly increased mRNA levels of Smad5 after 72h, but failed to enhance protein 
levels. Moreover, a reporter gene assay comprising the predicted seed match of miR-20a in the 3’ 
untranslated region (UTR) of Smad5 could not show a direct miRNA - mRNA interaction. 
Phosphorylation of Smad5 (normalised to Smad5 protein levels), however, showed a trend towards 
enhanced phosphorylation activity in stimulated as well as in unstimulated conditions as compared to 
antagomiR_MM controls, but these data did not reach statistical significance (supplementary Fig. S5). 
 
Proliferation of vascular smooth muscle cells is reduced upon transfection with antagomiR-20a 
Proliferation of pulmonary arterial smooth muscle cells is an essential part of the vascular remodelling 
in pulmonary hypertension; we thus addressed whether transfection with antagomiR-20a affects 
proliferation assessed by the BrdU assay. As shown in Figure 5a, proliferation was significantly 
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reduced in antagomiR-20a transfected HPASMC (A450nm: from 1.229 ± 0.182 to 0.867 ± 0.3) resulting 
in a reduction by 29.5% as compared to antagomiR_MM transfected controls (p = 0.018); conversely, 
when cells were transfected with precursor molecules of miR-20a (pre-miR-20a), proliferation was 
significantly increased (A450nm: from 1.049 ± 0.223 to 1.576 ± 0.418, or by 50.2 %, respectively. p = 
0.012). On the other hand, no significant changes were seen when apoptosis was analysed 
(Supplementary Fig. S6). AntagomiR-20a transfection of HPASMC resulted after 24h in up regulation 
of the cell cycle inhibitor p21 on protein level (antagomiR_MM: 0.232 ± 0.112 vs. antagomiR-20a: 
0.804 ± 0.077, p < 0.001 Fig. 5b) as well as on mRNA level (1.53 ± 0.43 fold, p = 0.051 Fig. 5c). The 
expression of miR-20a was analysed in the same samples showing down regulation of miR-20a in 
HPASMC by antagomir-20a treatment (Fig. 5d).   
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Discussion 
We have recently identified a microRNA-mediated signalling pathway that regulates the expression of 
BMPR2 on human pulmonary arterial endothelial cells 12. While this pathway might explain, at least in 
vitro, the reduced expression of BMPR2 as observed in several forms of pulmonary hypertension, the 
functional relevance of this pathway was unclear so far. A very recent study has confirmed the 
pathogenetic importance of the microRNA cluster 17/92 by inhibition of miR-17 in experimental 
pulmonary hypertension 17; based on our previous work that identified two functionally related miRs 
as regulators of BMPR2 expression, i.e. miR-17 and miR-20a but the latter one being more potent 12, 
we focused here on the action of miR-20a.  
In the present study we employed an established animal model of pulmonary hypertension and found 
that i) intraperitoneal injection of antagomiR in general is a feasible approach to efficiently 
downregulate distinct miRNAs in target tissues; ii) antagonisation of miR-20a reduces the hypoxia-
induced remodelling of pulmonary arterioles and, subsequently, reduces right heart hypertrophy in 
hypoxic animals; and,  iii), that treatment with antagomiR-20a restores functional expression levels of 
BMPR2 both in vivo and in vitro. 
In these experiments, antagonisation of miR-20a significantly reduced the vascular remodelling in 
hypoxic animals as assessed by wall thickness and luminal occlusion of small pulmonary arteries.  
Thickness of the vessel wall was less prominent than in hypoxic control animals, probably due to a 
lesser grade of muscularization upon reduced proliferation of vascular smooth muscle cells in the 
medial layer. The vascular occlusion of these vessels that is commonly observed in pulmonary 
hypertension and might result from vasoconstriction, proliferation of the intimal and medial layer and 
the development of plexiform lesions, has also been found to be reduced significantly in antagomiR-
20a treated animals. Vascular occlusion and narrowing of the pulmonary arterial lumen increase 
pulmonary vascular resistance and right ventricular afterload; these alterations result in cardiac 
hypertrophy and, ultimately, right heart failure.  In our experiments, antagomiR-20a treated animals 
revealed significantly less right ventricular hypertrophy than their mock-treated hypoxic controls, 
indicating improved pulmonary arterial hemodynamics in antagomiR-20a treated mice. However, 
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since the expression of miR-20a has been antagonised not only in the lungs, it remains unclear 
whether the observed reduction of right ventricular hypertrophy is an indirect effect of reduced 
pulmonary arterial pressure or, alternatively, whether it might be due to concomitant inhibition of 
miR-20a in cardiac myocytes. In contrast to other miRNAs, including miR-133 18 , miR-21 19 or miR-
27b 20 that also have been antagonised experimentally, miR-20a has not been described to be 
overexpressed in response to cardiac stress. With regard to other cell types, treatment with antagomiR-
20a did not significantly alter the hypoxia-induced polycythemia of erythrocytes, indicating that, at 
least, no such pleiotropic effects by antagonising miR-20a have occurred on hematopoietic cells.  
We further showed that treatment with antagomiR-20a increased the expression levels of BMPR2 in 
lung tissue, thus confirming indirectly that miR-20a targets the mRNA of BMPR2 as it was suggested 
previously by our in vitro data on human pulmonary arterial endothelial cells. Here, transfection of 
cells with antagomiR-20a could rescue expression and downstream signalling events of BMPR2 that 
was silenced by siRNA (supplemental material, Fig. S6). It has been discussed controversially, 
whether the observed dysregulation of BMPR2 in several forms of pulmonary hypertension might be 
of pathogenetic relevance. However, genetic studies and recent in vitro data suggest that BMPR2 and 
its downstream signalling play an important role in cell proliferation, vascular remodelling and, thus, 
in the development of pulmonary hypertension. For instance, Wong and co-workers showed that the 
activation of the BMPR2 signalling pathway in HPASMC leads to the inhibition of proliferation 
probably due to the induction of the cell cycle repressor p21 21. Our findings are along the line of these 
data and further provide evidence both in vivo and in vitro that a functional BMPR2 signalling 
prevents major vascular remodelling within small pulmonary arteries. In particular, we showed that 
the restoration of BMPR2 expression in lung tissue leads to activation of the BMP-2 target Id-2. 
Similarly, in vitro, stimulation of HPASMC with BMP-2 and transfection with antagomiR-20a 
revealed increased BMP-2 signalling as indicated by enhanced promoter activity of Id-1 and up 
regulated expression levels of Id-1 and -2. These transcription factors have been associated with cell 
proliferation 22; activated Id-1/-2 thus would reduce the proliferation rate of cells. Here, levels of Id-1 
and -2 have been found to be increased in antagomiR-20a treated HPASMC, and, in subsequent 
experiments, the proliferation of HPASMC was reduced by transfection of antagomiR-20a, whereas 
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apoptosis was not affected significantly. These data strongly indicate that the restoration of BMPR2 by 
treatment with antagomiR-20a is functional and, thus, reconstitutes the downstream signalling of 
BMPR2 in pulmonary arterial smooth muscle cells and in lung tissue. The reduced proliferation of 
smooth muscle cells was further shown to be associated with enhanced expression of the cell cycle 
repressor p21. We suggest that the observed increased expression of p21 by antagomiR-20a is caused 
by two ally acting mechanisms. On the one hand it was shown that miR-20a directly regulates the 
expression of p21 23, and on the other hand Wong et al. demonstrated that BMP-2 signalling enhances 
protein levels of p21 21. Therefore, antagomiR-20a treatment increases p21 levels by the inhibition of 
miR-20a and by enhancing BMP-2 signalling, which might result in growth arrest of smooth muscle 
cells. In summary, functional restoration of BMPR2 appears to inhibit the development of hypoxia-
induced vascular remodelling by enhanced intracellular signalling activity and reduced proliferation. 
Finally, antagonisation of miR-20a, one of the key microRNAs in pulmonary hypertension, was 
successfully achieved in hypoxic mice by repeated intraperitoneal injections. Since antagomiRs are 
employed to a growing extent for antagonisation of distinct microRNAs for pathogenetic 
investigations and therapeutic purposes 11,  these findings make antagomiRs to interesting tools for 
several reasons: downregulation of miR-20a was observed in target organs behind the liver, a finding 
that mutually excludes a significant hepatic first-pass effect; the effects have been longstanding, thus 
minimising the need for frequent applications; toxic effects have not been observed in terms of well-
being of the animals or interferon-gamma expression in liver tissue (data not shown). Moreover, to our 
knowledge, this is the first report on intraperitoneal application of antagomiRs. 
Our data might be limited by the fact that the increase of miR-20a observed under hypoxic conditions 
did not reach statistical significance. However, miRs are considered to act as fine tuners of gene 
regulation, and, thus, even small and non-significant elevations might have functional relevance. 
Accordingly, the increase of miR-20a and other members of the cluster miR-17/92 was rather small in 
other in vivo studies performed in experimental models of pulmonary hypertension 13. Together with 
these data, the experiments from our study underscore the major importance of a completely intact 
BMPR2 signalling pathway to prevent vascular remodelling; here, this could be achieved by specific 
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inhibition of miR-20a, an endogenously expressed repressor of BMPR2, resulting in normalization of 
BMPR2 mRNA levels or overexpression of protein levels, respectively.  
Taken together, we show here for the first time that the development of hypoxia-induced changes of 
small pulmonary arteries can be prevented by the application of antagomiR-20a, though it remains 
speculative whether this treatment would also reverse the once established disease. Our in vivo data, 
however, suggest that antagonisation of miR-20a inhibits vascular remodelling of pulmonary arteries 
in patients with pulmonary hypertension and, thus, might provide a major impact on our understanding 
and treatment of this disease. 
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Legends 
Figure 1 AntagomiR-20a suppresses miR-20a expression in vivo  
A. Study design of the in vivo experiments. 4 groups of 8 animals each were used; 3 groups were 
employed in conditions at 10% oxygen for up to 21 days and were treated with antagomiR-20a (25 
mg/kg), antagomiR_MM or PBS. Injections were performed at day 0, 5 and 12. One group was used 
as normoxic control. B. miR-20a expression as normalized to snoRNA202 is significantly 
downregulated upon treatment with antagomiR-20a in lung tissue. C. Sequence of antagomiR-20a and 
of the mismatch control, antagomiR_MM. 
Figure 2 AntagomiR-20a prevents pulmonary arterial vascular remodelling 
A. Representative images of small pulmonary arteries stained against α-smooth muscle actin showing 
reduced hypoxia-induced remodelling of intimal and medial vessel layer upon treatment with 
antagomiR-20a (second from left), quantified by analysis of lung vessel occlusion (B) and thickness of 
vessel wall (C). Similar findings were observed for heart morphometry as shown by representative 
images revealing reduced right ventricular hypertrophy by treatment with antagomiR-20a (D, second 
from left), heart weight relative to body weight (E) and heart hypertrophy (F). Hypoxia-induced 
erythrocytosis was not affected significantly by treatment with antagomiR-20a (G).  
Figure 3 Restoration of functional expression levels of BMPR2 by antagomiR-20a in mice 
Treatment with antagomiR-20a increased mRNA expression of BMPR2 in lung tissue as shown by 
qPCR (A), immunohistochemistry (B) (antagomiR-20a treated animals shown in upper panel, 
antagomiR_MM in lower panel, magnification 200fold) and, (C), Western blotting. Similarly, 
expression of Smad 5 (D) and Id-2 (E) was increased in lung tissue by treatment with antagomiR-20a.    
Figure 4 AntagomiR-20a enhances BMP-2 mediated signalling in vitro 
Expression of Id-1 (A) and Id-2 (B) is significantly increased after stimulation with BMP-2 when 
transfected with antagomiR-20a  (assessed at 1 and 4h). Dashed line indicates unstimulated HPASMC. 
C. For promoter studies, the promoter of human Id-1 was cloned containing multiple Smad 
 21 
transcription factor binding sites (as described in Lopez-Rovira et al. 15). D. Reporter gene assay in 
HepG2 cells: Co-transfection of pGL3basic-Id-1 and antagomiR_MM or antagomiR-20a. Stimulation 
with BMP-2 for 4h increased response in antagomiR-20a treated cells. E. Conversely, the response to 
BMP-2 was reduced when miR-20a was over expressed.   
Figure 5 Proliferation is reduced upon transfection with antagomiR-20a 
A.  BrdU assay performed in HPASMC after transfection of antagomiR-20a and antagomiR_MM 
showed significant inhibition of cell growth as measured by absorbance at 450nm. Conversely, 
transfection of pre-miRs increased proliferation significantly. B. p21 was found to be up regulated in 
antagomiR-20a transfected HPASMC as indicated by Western Blot (at 24h of antagomiR-20a 
transfection). C. mRNA levels of p21 were found to be increased in HPASMC when miR-20a 
expression was blocked as assessed by qPCR.  D. Proof of principle. miR-20a levels were found to be 
reduced upon transfection with antagomiR-20a. 
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